Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic index: A preliminary study

Journal of Medicinal Food

Volumn 12, Issue 6, 2009, Pages 1221-1226

  Nakamura, Teppei ^a   Mizutani, Jun ^a   Sasaki, Kouichi ^b   Yamamoto, Naoyuki ^a   Takazawa, Kenji ^c  

^a CALPIS Co Ltd   (Japan)

^b Samoncho Clinic   (Japan)

^c TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

Author keywords

Arterial stiffness; Casein hydrolysate; Central blood pressure; Ile Pro Pro; Lactotripeptides; Val Pro Pro

Indexed keywords

CASEIN HYDROLYSATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISOLEUCYLPROLYLPROLINE; LACTOTRIPEPTIDE DERIVATIVE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CENTRAL BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HEART RATE; HEMODYNAMIC INDEX; HEMODYNAMIC MONITORING; HEMODYNAMIC PARAMETERS; HUMAN; MALE; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; TABLET;

ADULT; BLOOD PRESSURE; CASEINS; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLIGOPEPTIDES;

EID: 74349129019     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2009.0159     Document Type: Article

References (30)

1. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
2. Roman MJ, Devereux RB, Kizer JR, et al.: Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: The Strong Heart Study. Hypertension 2007;50: 197-203.
3. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al.: Central blood pressure measurements and antihypertensive therapy. A consensus document. Hypertension 2007;50:154-160.
4. Blacher J, Asmar R, Djane S, London GM, Safar ME: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999;33:1111-1117.
5. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al.: Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam Study. Circulation 2006;113:657-663. (Pubitemid 43754329)
6. Asmar RG, London GM, O'Rourke ME, Safar ME: Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril=indapamide combination in hypertensive patient: A comparison with atenolol. Hypertension 2001; 38:922-926.
7. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.
8. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
10. Chagan L, Ioselovich A, Asherova L, Cheng JW: Use of alternative pharmacotherapy in management of cardiovascular diseases. Am J Manag Care 2002;8:270-285.
11. Kawasaki T, Seki E, Osajima K, et al.: Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J Hum Hypertens 2000;14:519-523.
12. Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T: Purification and characterization of angiotensin-I converting enzyme inhibitors from sour milk. J Dairy Sci 1995; 78:777-783.
13. Hata Y, Yamamoto N, Ohni M, Nakajima K, Nakamura Y, Takano T: A placebo-controlled study of the effects of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996;64: 767-771.
14. Mizuno S, Matsuura K, Gotou T, et al.: Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure or mild hypertension. Br J Nutr 2005;94:84-91. (Pubitemid 41357814)
15. Sano J, Ohki K, Higuchi T, et al.: Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food 2005;8:423-430.
16. Seppo L, Jauhiainen T, PoussaT, Korpela R: A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003;77:326-330.
17. Jauhiainen T, Vapaatalo H, Poussa T, Kyrönpalo S, Rasmussen M, Korpela R: Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens 2005;18:1600-1605.
18. Xu JY, Qin LQ, Wang PY, Li W, Chang C: Effect of milk tripeptides on blood pressure: A meta-analysis of randomized controlled trials. Nutrition 2008;24:933-940.
19. Boelsma E, Kloek J: Lactotripeptides and antihypertensive effects: A critical review. Br J Nutr 2009;101:776-786.
20. Hirota T, Ohki K, Kawagishi R, et al.: Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: Contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 2007;30:489-496.
21. Jauhiainen T, Rönnback M, Vapaatalo H, Wuolle K, Kautiainen H, Korpela R: Lactobacillus helveticus fermented milk reduces arterial stiffness in hypertensive subjects. Int Dairy J 2007;17: 1209-1211.
22. Matsuura K, Mizuno S, Nishimura S, Gotou T, Yamamoto N: Quantitative analysis of the antihypertensive peptides Val-Pro-Pro and Ile-Pro-Pro in casein hydrolyzate using an Aspergillus oryzae protease: An LC-MS method. Milchwissenschaft 2005; 60:24-27.
23. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A: Relationship between radial and central aortic pressure using the radial arterial pulse pressure. Hypertens Res 2007;30:219-228.
24. Waddell TK, Dart AM, Medley TL, Cameron JD, Kingwell BA: Carotid pressure is a better predictor of coronary artery disease severity than brachial pressure. Hypertension 2001;38:927-931.
25. Mitchell GF, Lacourcière Y, Arnold JM, Dunlap ME, Conlin PR, Izzo JL Jr: Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. Hypertension 2005;46:1111-1117.
26. McEniery CM, Wallace S, Mackenzie IS, et al.: Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006;48:602-608.
27. Nakamura Y, Masuda O, Takano T: Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem 1996;60:488-489.
28. Masuda O, Nakamura Y, Takano T: Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 1996;126:3063-3068.
29. van der Zander K, Jäkel M, Bianco V, Koning MM: Fermented lactotripeptides-containing milk lowers daytime blood pressure in high normal-to-mild hypertensive subjects. J Hum Hypertens 2008;22:804-806.
30. Yamaguchi N, Kawaguchi K, Yamamoto N: Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur J Pharmacol 2009;620:71-77.